There is a pressing need for new ways to treat disease, but drug development has become increasingly difficult due to high costs and failure rates. Human genetics has the power to transform drug development, because it uses human diversity to identify the basis of disease and resistance to it.
Global Partnership Network
Genetic studies are only as informative as the people in them. Variant Bio combines anthropology, epidemiology, genetics, and machine learning to identify relevant groups to partner with. We focus on outliers for traits of medical relevance and populations with rare genetic variants that rise to high frequency.
Using innovative low- and high-pass whole-genome sequencing alongside custom algorithms we can reduce costs without sacrificing data quality. Our approach is better suited to identify novel and population-specific genetic variants than genotyping arrays, and captures much more of the genome than exome-sequencing.
From Genomes to Targets
We look for associations between genetic variants and traits that have global medical relevance using statistical genetics. By focusing on outliers and unique populations, we can sequence fewer genomes to make novel discoveries.
Improving Global Health
We focus on therapeutic areas with global markets and unmet need including neurodegenerative, autoimmune, and cardiometabolic diseases.